The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI).
 
Yinan Shen
No Relationships to Disclose
 
Xingmei Liang
No Relationships to Disclose
 
Xinyan Jin
No Relationships to Disclose
 
Qian Tan
No Relationships to Disclose
 
Ronghua Zhao
No Relationships to Disclose
 
Guyue Wei
No Relationships to Disclose
 
Tian Fang
No Relationships to Disclose
 
Yuwei Li
No Relationships to Disclose
 
Lei Wang
No Relationships to Disclose
 
Shah Rahimian
No Relationships to Disclose
 
Jun Ding
No Relationships to Disclose
 
William Jia
No Relationships to Disclose
 
Manu Singh
No Relationships to Disclose
 
Yanal Murad
No Relationships to Disclose
 
Maoliang Huang
No Relationships to Disclose
 
Yuntao Zhang
No Relationships to Disclose
 
Guoming Shi
No Relationships to Disclose
 
Howard L. Kaufman
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Immuneering; Replimune
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Castle Biosciences; Marengo Therapeutics; Midatech Pharma; Tatum Bioscience; Virogin Biotech
 
Xueli Bai
No Relationships to Disclose
 
Tingbo Liang
No Relationships to Disclose